uniQure's FDA Application Predates Its 48-Month Huntington's Data, Which Missed Significance
The gene therapy maker's quarterly report says the 48-month readout was left out of its FDA filing, now under priority review with a May 1, 2027 target date.
uniQure, which develops one-time gene therapies for rare and other serious diseases, said in its 10-Q filed Wednesday that its Huntington's disease applications to the FDA and UK regulators predated the 48-month results, so those results were not part of either submission. In the 12 high-dose patients at that mark, the main goal of the analysis did not reach statistical significance.
From 75% slowing to 44%
The measure is cUHDRS, a composite Huntington's rating scale. At 48 months it showed a 44% slowing of disease progression against the updated external control, with a p-value of 0.144, which the company labels not significant. The prior quarter's filing described a 36-month readout on the same measure of a statistically significant 75% slowing (p=0.003).
The company's updated 36-month analysis of all 15 high-dose patients showed an 80% slowing on cUHDRS (nominal p=0.005). Total Functional Capacity, the primary measure for the confirmatory study, showed 61% slowing at 48 months (nominal p=0.008). The filing warns that those other results rest on nominal p-values not adjusted for multiplicity.
The filing also cautions that regulators could read the 48-month data differently than uniQure does, and that external controls are hampered by missing data and selection bias.
Why uniQure blames the control group
The company says data went missing in the matched external controls, reaching 53% at 48 months. Patients who dropped out of the control group were progressing materially faster than those who stayed, it says, which it believes understated disease progression in the control and so the treatment effect.
Comparing doses at 48 months, cUHDRS changed by -0.91 in the high-dose group against -1.94 in the low-dose group. The company calls that consistent with a dose-dependent effect.
Priority review and an advisory panel
The FDA accepted the application, filed under the accelerated approval pathway, with priority review and a target action date of May 1, 2027, the company announced Monday. In its acceptance letter the agency said it tentatively plans an advisory committee meeting, with timing still to be communicated to uniQure.
The confirmatory study design, agreed in key respects with the FDA, is a randomized trial of about 200 patients, split 2 to 1 between treatment and standard of care, with a 36-month primary endpoint. U.S. screening is planned by the end of 2026.
The prior filing recounted FDA feedback in December 2025 and March 2026 that external-control data were unlikely to be sufficient. After a June 2026 meeting, the company said it and the FDA agreed that a filing under accelerated approval was reasonable.
$768.4 million to fund into 2030
uniQure held $768.4 million in cash, cash equivalents and investment securities at September 30, 2026, against $622.5 million at the end of 2025. Management says that funds operations into 2030, including the confirmatory study and launch costs.
The net loss was $61.2 million for the third quarter, against $80.5 million a year earlier, and $195.8 million for the first nine months. The company's market value was about $1.7 billion in early Wednesday data.
The advisory committee date is still to be set, ahead of the May 1, 2027 target action date.
Sources
- 10-Q Filing — uniQure (QURE) — SEC EDGAR
- 10-Q Filing — uniQure (QURE), Q2 FY2026 filed 2026-07-29 (comparison basis) — SEC EDGAR
- 8-K Filing — uniQure, filed 2026-11-02 (Items 7.01, 8.01, 9.01) — SEC EDGAR
- Earnings release (8-K Item 2.02, tm2628930d1_ex99-1.htm) — uniQure, filed 2026-11-04 — SEC EDGAR